These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 985377)
21. Metabolism of branched-chain amino acids in fibroblasts from patients with maple syrup urine disease and other abnormalities of branched-chain ketoacid dehydrogenase activity. Yoshida I; Sweetman L; Nyhan WL Pediatr Res; 1986 Feb; 20(2):169-74. PubMed ID: 3080729 [TBL] [Abstract][Full Text] [Related]
22. Clinical consequences of disorders in the intermediate metabolism of branched chain amino acids (valine, leucine and isoleucine). Mogoş T; Cheţa CP; Mincu IT Rom J Intern Med; 1994; 32(1):57-61. PubMed ID: 8081313 [TBL] [Abstract][Full Text] [Related]
23. [Acrodermatitis enteropathica-like syndrome secondary to branched-chain amino acid deficiency during treatment of maple syrup urine disease]. Templier I; Reymond JL; Nguyen MA; Boujet C; Lantuejoul S; Beani JC; Leccia MT Ann Dermatol Venereol; 2006 Apr; 133(4):375-9. PubMed ID: 16733455 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the catabolism of branched-chain L-amino acids in cultured human skin fibroblasts. Schadewaldt P; Wendel U Pediatr Res; 1987 Nov; 22(5):591-4. PubMed ID: 3684388 [TBL] [Abstract][Full Text] [Related]
25. [Studies on "branched chain oxoacid aciduria" (maple syrup diseases)]. Goedde HW; Blume KG; Möhlenbeck F; Rotthauwe HW; Simon HA; Lang K Med Klin; 1966 Dec; 61(52):2063-7. PubMed ID: 4385693 [No Abstract] [Full Text] [Related]
26. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Morton DH; Strauss KA; Robinson DL; Puffenberger EG; Kelley RI Pediatrics; 2002 Jun; 109(6):999-1008. PubMed ID: 12042535 [TBL] [Abstract][Full Text] [Related]
27. Plasma amino acid analyses in two cases of maple syrup urine disease. Surarit R; Srisomsap C; Wasant P; Svasti J; Suthatvoravut U; Chokchaichamnankit D; Liammongkolkul S Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 2():138-9. PubMed ID: 11400750 [TBL] [Abstract][Full Text] [Related]
28. Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease. Schadewaldt P; Hammen HW; Ott AC; Wendel U J Inherit Metab Dis; 1999 Aug; 22(6):706-22. PubMed ID: 10472531 [TBL] [Abstract][Full Text] [Related]
29. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine. Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005 [TBL] [Abstract][Full Text] [Related]
30. Definition of the mutation responsible for maple syrup urine disease in Poll Shorthorns and genotyping Poll Shorthorns and Poll Herefords for maple syrup urine disease alleles. Dennis JA; Healy PJ Res Vet Sci; 1999 Aug; 67(1):1-6. PubMed ID: 10425233 [TBL] [Abstract][Full Text] [Related]
31. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. Deon M; Guerreiro G; Girardi J; Ribas G; Vargas CR Int J Dev Neurosci; 2023 Oct; 83(6):489-504. PubMed ID: 37340513 [TBL] [Abstract][Full Text] [Related]
32. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Barschak AG; Sitta A; Deon M; Barden AT; Dutra-Filho CS; Wajner M; Vargas CR Metab Brain Dis; 2008 Mar; 23(1):71-80. PubMed ID: 18026828 [TBL] [Abstract][Full Text] [Related]
33. A new variant of maple syrup urine disease (branched chain ketoaciduria). Clinical and biochemical evaluation. Schulman JD; Lustberg TJ; Kennedy JL; Museles M; Seegmiller JE Am J Med; 1970 Jul; 49(1):118-24. PubMed ID: 5431474 [No Abstract] [Full Text] [Related]
34. THE DIAGNOSIS OF MAPLE SYRUP URINE DISEASE (BRANCHED- CHAIN KETOACIDURIA) BY THE IN VITRO STUDY OF THE PERIPHERAL LEUKOCYTE. DANCIS J; HUTZLER J; LEVITZ M Pediatrics; 1963 Aug; 32():234-8. PubMed ID: 14044451 [No Abstract] [Full Text] [Related]
35. [CLINICAL, BIOCHEMICAL, AND NEUROPATHOLOGIC ASPECTS OF MAPLE SYRUP URINE DISEASE. A KETOACIDURIA OF THE OPEN CHAIN AMINOACIDS LEUCINE, ISOLEUCINE AND VALINE]. SILBERMANSCHWARTZMAN J An Fac Med Lima; 1963 Sep; 46():339-65. PubMed ID: 14122039 [No Abstract] [Full Text] [Related]
36. Variant maple syrup urine disease in mother and daughter. Zaleski LA; Dancis J; Cox RP; Hutzler J; Zaleski WA; Hill A Can Med Assoc J; 1973 Aug; 109(4):299-300 passim. PubMed ID: 4730202 [TBL] [Abstract][Full Text] [Related]
37. Treatment of the acute crisis in maple syrup urine disease. Nyhan WL; Rice-Kelts M; Klein J; Barshop BA Arch Pediatr Adolesc Med; 1998 Jun; 152(6):593-8. PubMed ID: 9641714 [TBL] [Abstract][Full Text] [Related]
38. Administration of branched-chain amino acids alters epigenetic regulatory enzymes in an animal model of Maple Syrup Urine Disease. Streck EL; Bussular FP; Wessler LB; Duarte MB; Rezende VL; Rodrigues MS; Torres CA; Lemos IS; Candiotto G; Gava FF; de Oliveira J; Valvassori SS Metab Brain Dis; 2021 Feb; 36(2):247-254. PubMed ID: 33098071 [TBL] [Abstract][Full Text] [Related]
39. Alloisoleucine formation in maple syrup urine disease: isotopic evidence for the mechanism. Matthews DE; Ben-Galim E; Haymond MW; Bier DM Pediatr Res; 1980 Jul; 14(7):854-7. PubMed ID: 7413299 [TBL] [Abstract][Full Text] [Related]
40. Apoptotic signaling pathways induced by acute administration of branched-chain amino acids in an animal model of maple syrup urine disease. Vilela TC; Scaini G; Furlanetto CB; Pasquali MA; Santos JP; Gelain DP; Moreira JC; Schuck PF; Ferreira GC; Streck EL Metab Brain Dis; 2017 Feb; 32(1):115-122. PubMed ID: 27510712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]